Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
Erythema multiforme-like drug eruption in a patient with mycosis fungoides on durvalumab and lenalidomide.
Journal: JAAD case reports
Published: September 01, 2026
Impact of Conditioning Regimen Intensity and Total Body Irradiation on Outcomes of Allogeneic Hematopoietic Cell Transplantation for Mature T-Cell Lymphomas: A Multicenter Analysis.
Journal: Transplantation and cellular therapy
Published: July 08, 2026
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 22, 2026
Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 21, 2026
Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression.
Journal: JAAD case reports
Published: March 20, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.
Journal: British journal of haematology
Published: December 22, 2025
T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.
Journal: JAMA dermatology
Published: October 22, 2025
Recurrence of mogamulizumab-associated rash in patients with relapsed erythrodermic cutaneous T-cell lymphoma after retreatment with mogamulizumab.
Journal: JAAD case reports
Published: September 11, 2025
SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 05, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Journal: Blood advances
Published: April 15, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Journal: Blood advances
Published: April 15, 2025
Last Updated: 09/26/2026